NUVB ▼ -0.5% - Nuvation Bio Inc. $NUVB - Nuvation Bio Announces New Analyses Reinforcing the Durable, Consistent Efficacy of IBTROZI® (taletrectinib) Across Key Patient Subgroups in Advanced ROS1+ NSCLC at 2026 World Conference on Lung Cancer Nuvation Bio announced new analyses at the World Conference on Lung Cancer reinforcing the durable efficacy of its IBTROZI treatment across key patient subgroups with advanced ROS1-positive non-small cell lung cancer, though the stock declined 0.5% today despite the positive clinical data presentation. 15-SEP-2026 08:04 AM ET